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Multiple sclerosis (MS) is an inflammatory disease of the CNS that is characterized by BBB dysfunction and 
has a much higher incidence in females. Compared with other strains of mice, EAE in the SJL mouse strain 
models multiple features of MS, including an enhanced sensitivity of female mice to disease; however, the 
molecular mechanisms that underlie the sex- and strain-dependent differences in disease susceptibility have 
not been described. We identified sphingosine-1-phosphate receptor 2 (S1PR2) as a sex- and strain-specific, 
disease-modifying molecule that regulates BBB permeability by destabilizing adherens junctions. S1PR2 
expression was increased in disease-susceptible regions of the CNS of both female SJL EAE mice and female 
patients with MS compared with their male counterparts. Pharmacological blockade or lack of S1PR2 signal-
ing decreased EAE disease severity as the result of enhanced endothelial barrier function. Enhanced S1PR2 
signaling in an in vitro BBB model altered adherens junction formation via activation of Rho/ROCK, CDC42, 
and caveolin endocytosis-dependent pathways, resulting in loss of apicobasal polarity and relocation of ablu-
minal CXCL12 to vessel lumina. Furthermore, S1PR2-dependent BBB disruption and CXCL12 relocation were 
observed in vivo. These results identify a link between S1PR2 signaling and BBB polarity and implicate S1PR2 
in sex-specific patterns of disease during CNS autoimmunity.
Introduction
Multiple sclerosis (MS) is an autoimmune, demyelinating disease 
of the CNS that has a strong sex bias, with the female to male ratio 
currently ranging from 3:1 to 4:1 (1–3). Relapsing-remitting MS 
(RRMS), the most common form of the disease in women and 
men, is a condition in which recurrent relapses of new neurological 
dysfunction (relapses) are separated by periods of clinical stability. 
The mechanisms underlying sex differences in MS and whether 
they predominantly affect immune responses, CNS susceptibility 
to inflammation, or both are unclear.
EAE in the inbred SJL mouse strain is commonly used to model 
the sexual dimorphism observed in MS. Female SJL mice exhibit 
increased sensitivity to EAE and a relapsing-remitting phenotype, 
while male SJL mice exhibit monophasic disease resembling EAE 
induced in both sexes of other mouse strains, such as C57BL/6. 
Gonadal hormones and epigenetic regulation of sex chromosomes 
are postulated to contribute to sex differences in SJL mice during 
EAE and other autoimmune disorders (4, 5). Several studies also 
indicate that the CNS itself may be responsible for the observed 
sex differences in disease expression, primarily via alterations in 
endothelial cell–mediated regulation of immune cell entry (6–9).
Studies of endothelium in peripheral organs implicate cadher-
ins and sphingosine-1-phosphate (S1P) signaling in mediating 
alterations in cadherin-dependent barrier properties between 
endothelial cells (10). Cadherins are plasma membrane proteins 
associated with adherens junctions (AJs), whose expression at 
cell-cell contacts depends on endocytic transport (11–13). Vascu-
lar endothelial–cadherin (VE-cadherin) expression is required for 
CNS endothelial polarity and vascular lumen organization (14), 
and cytokine-mediated alterations in VE-cadherin expression in 
CNS endothelium influence leukocyte entry (15, 16). S1P, a bio-
active metabolite of sphingolipids, is produced by erythrocytes in 
the plasma, vascular and lymphatic endothelial cells, and neuronal 
lineage cells within the CNS (17–19). S1P signals via 5 G pro-
tein–coupled receptors (S1PRs) to regulate various physiological 
responses, including vascular permeability (20–22). Endothelia 
express different combinations of S1P receptors (S1PRs), which 
regulate endothelial cell survival, migration, AJ assembly, and bar-
rier integrity (20, 21, 23). S1PRs have received considerable atten-
tion in the MS field due to recent success with the broad S1PR 
inhibitor, fingolimod (FTY720-phosphate), which binds to S1PR 
subtypes S1PR1, S1PR3, S1PR4, and S1PR5 but not S1PR2 (24), 
and inhibits vascular endothelial cell growth factor–induced vas-
cular permeability in vivo (22). Several in vivo studies demonstrate 
roles for S1PR2 in vascular biology, including regulation of portal 
vein pressure (25), the formation of atherosclerotic plaques (26), 
inflammation (27), and retinal angiogenesis (28). In vitro studies 
implicate S1PR2 in the regulation of vascular integrity via phos-
phorylation of VE-cadherin, preventing its translocation to cell-
cell contact sites (29). The expression or function of S1PR2 at 
endothelial barriers within the CNS or during induction of CNS 
autoimmunity has not been investigated.
Here, we identify a sexually dimorphic target for the treatment 
of relapsing-remitting CNS autoimmunity. Microarray analysis 
of specimens from naive male and female adult SJL mice revealed 
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a significant increase in the expression of S1PR2 in disease-sus-
ceptible CNS regions only in females. Expression and activity of 
S1PR2 were associated with decreased VE-cadherin at AJs and 
reversal of endothelial cell polarity, as assessed by movement of 
the abluminal chemokine CXCL12 (30–32) to lumenal locations. 
Naive female SJL mice exhibited relocation of CXCL12 along ven-
ule lumina exclusively in white matter compared with naive male 
SJL mice and both sexes of other murine strains. S1PR2-deficient 
mice and female, but not male, SJL mice treated with the S1PR2 
antagonist, JTE-013, each exhibited decreased disease severity 
during EAE induced by active immunization with myelin peptide, 
accompanied by diminished lymphocyte entry, persistent ablu-
minal expression of CXCL12, and decreased BBB permeability to 
fluorescein. S1PR2 appears to play an essential role in regulating 
CNS endothelial polarity, which influences lumenal localizing 
cues and capture of infiltrating lymphocytes.
Results
Whole transcriptome analyses of sexually dimorphic genes detects elevated 
S1PR2 in disease-susceptible CNS regions in naive female SJL mice. The 
inbred SJL mouse strain has been used as a model of the sexual 
dimorphism observed in MS, as female SJL mice are more suscep-
tible to EAE than male SJL mice and exhibit a relapsing-remitting 
disease pattern similar to that observed in patients with MS (33). 
We hypothesized that sexual dimorphism in this MS model arises 
from sexually dimorphic and CNS-region specific expression of 
genes that regulate BBB permeability and leukocyte entry. Thus, 
we used a whole transcriptome microarray to identify sexually 
dimorphic RNA transcripts that are differentially expressed in dis-
ease-susceptible versus nonsusceptible CNS regions of male and 
female SJL mice. Profiling total RNA from the cerebella and fron-
tal cortices of naive female SJL mice versus male SJL mice revealed 
differential expression of 44 and 23 gene transcripts, respectively, 
with 20 being unique to the cerebellum (Table 1 and Supplemen-
tal Table 1; supplemental material available online with this arti-
cle; doi:10.1172/JCI73408DS1). Sixteen of these transcripts have 
uncharacterized genetic function and are only identified by their 
locus link or RIKEN database numbers (Supplemental Table 1). Fif-
teen of these uncharacterized loci are linked to the Y chromosome, 
and one is autosomal. The 3 loci that were dimorphic in both cor-
tex and cerebellum are linked to the X or Y chromosomes, includ-
ing Xist, which regulates X-chromosome inactivation (Table 1). 
Of the 4 novel autosomal loci that were unique to the cerebellum, 
2 were of interest for autoimmune disease: the IL-20 receptor b, 
a receptor associated with skin autoimmune diseases (34–37), 
and sphingosine-1-phosphate receptor 2 (S1PR2), which regu-
lates vascular permeability in peripheral organs (refs. 29, 38, 39, 
and Figure 1A). Because S1PR2 belongs to a family of G protein–
coupled receptors expressed by cells of the vascular, immune, 
and nervous systems and S1PR2 signaling, in particular, disrupts 
endothelial AJs, we focused our studies in CNS autoimmunity on 
this protein (29). Quantitative PCR (QPCR) evaluation of sexually 
dimorphic expression of S1PR2 in cerebella of SJL mice validated 
microarray results (P = 0.0255) (Figure 1B). Western blot analy-
sis confirmed microarray and QPCR data, revealing significantly 
enhanced expression of S1PR2 in the cerebella of naive female SJL 
mice compared with that in male SJL mice (P < 0.05), while no sex-
ual dimorphism was observed in naive C57BL/6 mice (Figure 1C), 
and whole brain extracts from S1PR2-deficient mice confirmed 
antibody specificity (Supplemental Figure 1A). Of interest, West-
ern blot examination of S1PR2 levels within the cerebella of naive 
SJL-Chr YB10.S male mice compared with those of SJL male and 
female mice did not suggest that a Y-chromosome polymorphism 
(40) is responsible for sexually dimorphic S1PR2 expression in the 
CNS of SJL mice (Supplemental Figure 2).
Because S1PR2 has known roles in vascular biology, we assessed 
disruption of the BBB, via administration of sodium fluorescein to 
naive male and female animals of both B6 and SJL backgrounds. 
Consistent with increased S1PR2 expression in the cerebella of 
naive female SJL animals, fluorescein permeability was significantly 
increased in the cerebella of naive female SJL mice compared with 
that in male mice (P < 0.01) (Figure 1D). Similar to wild-type B6 
mice, S1PR2-deficient mice and their wild-type controls, which are 
both on a 129S/B6 background, do not exhibit sexual dimorphism 
and deficiency of S1PR2 does not alter BBB permeability in naive 
animals (Supplemental Figure 1B). Immunohistochemical detec-
tion of extravasated albumen in CNS white matter of naive SJL 
mice also exhibited sexual dimorphism (Figure 1E). Of note, sexual 
dimorphism in S1PR2 expression and vascular permeability was not 
observed in the spinal cord, which is a disease-susceptible CNS region 
in SJL mice. In addition, alterations in levels of claudin 5, as assessed 
Table 1
Sexually dimorphic genes or loci in naive SJL cerebella and 
frontal cortices
 Fold change  
 (female vs. male)
Gene symbol CB CTX Chromosome
Known X- or Y-linked loci   
Xist 3.837A 3.544B X
Utx 1.341A 1.317B X
Eif2s3x 1.277 1.348B X
Igsf1 1.043 –1.897B X
Timp1 –1.215 –1.519B X
Ddx3y –11.042 –9.345B Y
Novel X- or Y-linked loci
A830055109Rik –1.203 1.524B X
LOC673556 –1.598 –1.072 Y
4930579N16Rik –1.978 –1.100 Y
Autosomal
R3hdm1 –1.035 1.441B 1
Ppp1r1c 1.039 1.373B 2
Hsd3b2 –1.037 1.400B 3
Cort 1.021 1.327B 4
Csda –1.564 –1.166 6
Apoc1 –1.004 –1.411B 7
Zfhx3 –1.012 –1.301B 8
S1pr2 1.311 –1.092 9
Il20rb –1.367 1.006 9
Foxk2 1.016 1.415B 11
Idb2 –1.168 1.377B 12
Nefm 1.337 –1.038 14
Sdf2l1 –1.017 –1.339B 16
Adcyap1 1.076 1.365B 17
Cd6 1.015 1.347B 19
Summary of sexually dimorphic genes or loci in SJL cerebella (CBA) 
and frontal cortices (CTXB) and chromosome locations. Four novel 
autosomal loci were differentially expressed in the female cerebella 
(shown in bold).
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by Western blotting, did not exhibit sexual dimorphism in naive B6 
or SJL mice (Supplemental Figure 3). Immunohistochemistry (IHC) 
analysis of cellular sources of S1PR2 in the CNS of naive female and 
male SJL mice revealed localization mostly along endothelial cells, 
with some astrocytes and pericytes as additional sources (Figure 2).
Female SJL mice and humans exhibit increased vascular S1PR2 during 
CNS autoimmunity. To assess sexually dimorphic alterations in BBB 
permeability during CNS autoimmunity, we administered sodium 
fluorescein to male and female animals of both B6 and SJL back-
grounds after induction of EAE via immunization with appropri-
ate myelin peptides. During the course of EAE, fluorescein perme-
ability increased in all CNS regions in both sexes and strains, with 
significantly higher permeability in female SJL mice compared 
with that in male SJL mice at peak of disease and during remission 
in cortices (peak: P < 0.05; remission: P < 0.05) and cerebella (peak: 
P < 0.05; remission: P < 0.001) (Figure 3A). Expression of S1PR2 
was also sexually dimorphic during EAE, as S1PR2 expression 
was increased in disease-susceptible regions (cerebella: P < 0.05; 
spinal cord: P < 0.001) in female SJL mice at peak of EAE, with 
no detectable differences in cortices (Figure 3B). Again, no such 
sexual dimorphism was observed in C57BL/6 mice. Although ova-
riectomy and estrogen exposure affect disease in female SJL mice 
(33, 41–45), levels of S1PR2 expression in all CNS regions of naive 
female SJL mice or of female SJL mice immunized with proteolipid 
protein epitope 139–151 (PLP139–151) were unaffected by ovariec-
tomy, with or without 17β-estradiol replacement (Supplemental 
Figure 4). Of note, sham-ovariectomized and ovariectomized mice 
were evaluated when they attained clinical scores of 2, whereas 
ovariectomized mice treated with 17β-estradiol did not develop 
symptomatic EAE. Thus, suppression of clinical symptoms by 
17β-estradiol in PLP139–151–immunized mice did not affect CNS 
levels of S1PR2 expression. These data are also consistent with 
studies demonstrating that 17β-estradiol does not affect systemic 
inflammation in the setting of active immunization (41).
Figure 1
S1PR2 exhibits sexually dimorphic gene expression within the CNS of naive SJL mice. (A) Microarray analysis of S1PR2 and IL-20RB expression 
within cerebella (CB) (green) of female (red circles) and male (blue circles) littermates demonstrates significant alterations compared with frontal 
cortices (FCX) (purple). In box-and-whisker plots, horizontal bars indicate the medians, boxes indicate 25th to 75th percentiles, and whiskers 
indicate 10th and 90th percentiles. Data are expressed as fold change ± SEM and as individual values of Illumina probe levels. P < 0.05, ANOVA 
for sex- and region-specific gene expression (cerebella only). (B) QPCR evaluation of S1PR2 expression in cortices (CTX), cerebella, and spinal 
cords (SC) of same cohort. Data are expressed as mean S1PR2/GAPDH copies ± SEM for female (red bars) and male (blue bars) samples 
(n = 5). *P < 0.05, 2-way ANOVA. (C) Western blot analysis of S1PR2 in cortices, cerebella, and spinal cords in male (B6: light blue bars; SJL: 
blue bars) and female (B6: pink bars; SJL: red bars) C57BL/6 and SJL mice. Data are expressed as mean ± SEM densities normalized to male B6 
(n = 5). *P < 0.05, 2-way ANOVA. (D) Male (light and dark blue bars) and female (pink and red bars) naive C57BL/6 and SJL mice were exam-
ined for BBB Na-Fluorescein permeability within cortices, cerebella, and spinal cords, normalized to sera values for individual mice (5–8 mice 
per group). Data are reported as arbitrary fluorescence values, normalized to mean ± SEM values for naive male C57BL/6 in each CNS region. 
**P < 0.01. (E) Immunohistochemical detection of albumen in cortices, cerebella, and spinal cords of naive female and male SJL mice. Scale bar: 
25 μm. Images are representative of 3 images each from 2 to 3 mice per sex.
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S1PR2 immunoreactivity was localized to endothelium, ves-
sel-associated astrocytes, and occasional pericytes within the 
CNS of SJL mice with EAE (Figure 3C) and within human post-
mortem cerebellar specimens derived from patients with and 
without MS (Supplemental Table 2 and Figure 4, A and B). Fur-
thermore, quantitative IHC assessment of human specimens 
showed significantly higher levels of vessel-associated S1PR2 in 
patients with MS compared with that in patients without MS 
(P = 0.01) and a trend toward increased S1PR2 expression in 
female patients with MS compared with that in male patients 
with MS (Figure 4C). Of interest, the highest levels of S1PR2 
expression in female patients with MS were in those with RRMS 
(2 cases), and the 1 male patient with high levels of S1PR2 had 
a history of occipital head trauma. These results suggest that 
S1PR2 may play a role in sexually dimorphic patterns of BBB 
dysfunction in the setting of CNS autoimmunity.
Clinical disease severity and BBB permeability during EAE are reduced 
by pharmacologic or genetic inactivation of S1PR2. To investigate 
whether S1PR2 modulates the pathogenesis of EAE, we evaluated 
clinical disease scores in the setting of both pharmacologic block-
ade and genetic deletion of S1PR2. Female SJL mice treated with 
the specific S1PR2 antagonist JTE-013 (1.5 mg/kg) (46), begin-
ning when mice reached a clinical score of 2 and continuing for 
10 (Figure 5A, top) or 30 (Figure 5A, bottom) days, exhibited less 
severe daily clinical scores (P < 0.0001, both lengths of treatment), 
maximum severity scores (P < 0.0001, both lengths of treatment), 
and mean cumulative scores (P < 0.01 for 10 days treatment, 
P < 0.001 for 30 days treatment), while male SJL mice did not 
respond to treatment (Supplemental Figure 5). No changes in 
body weight were observed after JTE-013 treatment, regardless of 
treatment duration (Supplemental Figure 6, A–C). Consistent with 
clinical assessments, H&E staining revealed significantly fewer 
inflammatory foci within the white matter of both spinal cords 
(P < 0.01) and cerebella (P < 0.05) of JTE-013 mice compared with 
that in vehicle-treated female SJL mice at peak of EAE (Figure 5B), 
and cerebellar lesions were significantly reduced (P < 0.05) during 
remission. Luxol fast blue (LFB) staining further revealed that JTE-
013 treatment reduced demyelination of spinal cords and cerebellar 
white matter during peak and remission phases of EAE (Figure 5B). 
Female SJL mice with EAE treated with JTE-013 for 5 days also 
exhibited significantly reduced fluorescein permeability in both 
cerebella (P < 0.001) and spinal cords (P < 0.01), compared with 
Figure 2
S1PR2 is primarily expressed by CNS endothelial cells. (A) Immunofluorescence detection of S1PR2 (red) in female and male SJL endothelial 
cells (CD31, green), located in the cortex, cerebellum, and spinal cord and in spinal cord astrocytes (GFAP, green). Arrowheads identify S1PR2+ 
astrocytes. (B) Immunofluorescence detection of S1PR2 (green) in female and male SJL pericytes (PDGF-Rβ, red), located in the cortex, cere-
bellum, and spinal cord. (C) Immunofluorescence detection of S1PR2 (red) in spinal cords of 129S/B6 wild-type and S1pr2–/– mice. All nuclei were 
stained with Topro3 (blue). Scale bar: 25 μm. Data are representative of 10 images each from 5 female and 5 male animals.
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vehicle controls (Figure 5C, top) and a significant reduction in 
spinal cord permeability after prolonged treatment for 30 days 
(P < 0.01) (Figure 5C, bottom). Similar results were observed via 
immunohistochemical detection of extravasated albumen within 
the white matter of diseases mice (Supplemental Figure 7A).
Consistent with results after antagonist treatment, S1PR2-de-
ficient mice immunized with MOG35–55 exhibited significantly 
decreased severity of EAE compared with that of wild-type con-
trols, indicated by lower daily clinical scores (P < 0.0001), max-
imum severity scores (P < 0.0001), and mean cumulative scores 
Figure 3
Female SJL mice exhibit sexually dimorphic enhancement of BBB permeability and S1PR2 expression during EAE. (A) Male and female C57BL/6 
and SJL mice at peak of EAE (clinical score of 3 to 4) or first remission (clinical score of 2) were examined for BBB permeability to Na-Fluorescein 
within cortices, cerebella, and spinal cords, normalized to sera values for individual mice (5–8 mice per group). Data are reported as arbitrary 
fluorescence values, normalized to mean values for naive male C57BL/6 in each CNS region. (B) Protein lysates from CNS regions of male and 
female C57BL/6 and SJL mice at peak of EAE (clinical scores of 3 to 4) were probed for S1PR2 (red), with β-tubulin (green) as a loading control. 
Data are reported as density values of S1PR2 normalized to density values for β-tubulin. Data are normalized to mean values for male C57BL/6 
mice in each CNS region. (A and B) Bar graphs depict mean ± SEM findings for male (B6: light blue bars; SJL: blue bars) and female (B6: light 
red bars; SJL: red bars) for 4 mice per group. *P < 0.05; ***P < 0.001, 2-way ANOVA. (C) Immunofluorescence detection of S1PR2 (red, top and 
middle; green, bottom) in vessels (CD31, green), astrocytes (GFAP, green), and pericytes (PDGF-Rβ, red, bottom) in cortices, cerebella, and 
spinal cords of female SJL mice at peak of EAE. All nuclei were stained with Topro3 (blue). Scale bar: 25 μm. Data are representative of 10 images 
each from 5 male and 5 female animals. Arrows indicate areas of colocalization.
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(P < 0.0001) (Figure 6A). S1pr2–/– animals also exhibited less demy-
elination and fewer inflammatory foci during peak of EAE, com-
pared with wild-type mice, in the spinal cords (P = 0.03) but not 
the cerebella (Figure 6B), in addition to significant reductions in 
fluorescein permeability in the spinal cords during both acute 
(P < 0.01) and chronic (P < 0.01) EAE (Figure 6C). There was also less 
detection of extravasated albumen in the spinal cords of S1pr2–/– 
mice compared with that in wild-type animals at peak of disease 
(Supplemental Figure 7B).
S1PR2 signaling enhances BBB permeability via caveolin-endocytosis, 
Rho/ROCK, and CDC42-dependent pathways. To further assess the 
impact of S1PR2 signaling on BBB function, we used a well-char-
acterized transwell in vitro model of the BBB consisting of human 
cerebral microvascular endothelial cells (HCMECs) grown on 
porous filter membranes over primary human astrocytes (47). 
Barrier integrity was evaluated by electrode recording of transen-
dothelial electrical resistance (TEER). Treatment with exogenous 
S1P permeabilized in vitro BBBs in a dose-dependent manner over 
the course of 4 hours, indicated by significant reductions in TEER 
(P < 0.001, all comparisons) (Figure 7A). This disruption of bar-
rier integrity was S1PR2 dependent, as treatment with an S1PR2 
antagonist (Figure 7B), but not an S1PR1 antagonist (Figure 7C), 
rescued TEER reduction after S1P treatment. Moreover, treatment 
with an S1PR1-specific agonist led to a small increase in TEER in 
both vehicle- and S1P-treated cultures (P < 0.05) (Supplemental 
Figure 8A), in contrast to the TEER decreases produced by S1P via 
S1PR2. Use of RNA interference to specifically knockdown S1PR1 
and S1PR2 similarly demonstrated S1PR2-dependent disruption 
Figure 4
BBB expression of S1PR2 is increased in MS. (A) Endothelial cell (CD31, green) and (B) astrocyte (GFAP, green) localization of S1PR2 (red) in 
female and male cerebellar tissue obtained from patients with and without MS. Nuclei are counterstained with Topro3 (blue). (A) Control stains, in 
which sections were first blocked with immunogen (1 mg/ml) prior to detection of CD31 (green) and S1PR2 (red), are included. Scale bar: 25 μm. 
(C) Quantification of amounts of vessel-associated S1PR2 fluorescence in female (red circles) and male (blue circles) samples from patients 
with and without MS. Levels of S1PR2 fluorescence were determined by examining S1PR2 staining in venule ROIs in 10 images per patient (4–6 
patients per group), normalized by area of CD31 staining to control for size and numbers of vessels. Note that the outlier in the male MS group 
also had a history of occipital head trauma. *P < 0.05. Horizontal bars represent geometric means.
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of barrier integrity (Supplemental Figure 9, A and B). Further 
characterization of the signaling components that contribute to 
S1PR2 dysregulation of the in vitro BBB revealed that pharma-
cological blockade of the caveolin-dependent endocytic pathway 
(Figure 7D) prior to S1P treatment prevented TEER reductions 
(P < 0.001), while blockade of clathrin-dependent endocytosis 
(Supplemental Figure 8B) or macropinocytosis (Supplemental 
Figure 8C) produced either small or no changes in TEER after S1P 
administration, respectively. TEER reductions after S1P treatment 
were also prevented by pretreatment with inhibitors of the Rho 
GTPase effectors Rho/ROCK (P < 0.001) (Figure 7E) and CDC42 
(P < 0.001) (Figure 7F) but not Rac (Supplemental Figure 8D).
S1PR2 signaling leads to breakdown of AJs and loss of polarized expres-
sion of CXCL12 on basolateral/abluminal surfaces. We next examined 
whether S1PR2-dependent disruption of BBB function resulted 
in molecular changes to the structure of the BBB endothelium. 
Similar to results with TEER recording, S1P treatment resulted 
in a breakdown of AJs, indicated by loss of intensity and discrete-
ness of VE-cadherin staining at intercellular borders (Figure 7G, 
left). Diminished AJ integrity was also associated with a loss of 
polarized protein expression on the apical and basolateral sur-
faces of endothelial cells, as assessed via z-plane confocal micros-
copy (imaging on same plan of microscopy z axis) for canonical 
markers of apical (γ-glutamyltransferase-1 [GGT]) and basolateral 
(CXCL12) BBB surface markers (Figure 6G, right). Again, loss of AJ 
integrity and polarized GGT/CXCL12 expression after S1P treat-
ment was specific to S1PR2, as it could be reversed by JTE-013 
treatment (Figure 7H) but not by treatment with a specific antag-
onist (Figure 7I) or agonist of S1PR1 (Supplemental Figure 8E). 
Knockdown of S1PR2, but not S1PR1, RNA in the context of S1P 
treatment also led to loss of AJ integrity (Supplemental Figure 9C). 
Similarly, pretreatment with inhibitors of caveolin-dependent 
endocytosis (Figure 7J) and Rho/ROCK or CDC42 (Figure 7, 
K and L) prevented loss of AJs and endothelial polarity, while inhi-
bition of clathrin-dependent endocytosis, macropinocytosis, and 
Rac (Supplemental Figure 8, F–H) had no effect.
Given the mouse strain- and sex-specific differences in CNS lev-
els of expression of S1PR2, we next analyzed polarized CXCL12 
expression at the BBB in naive female and male mice of various 
strains susceptible to EAE via quantification of fluorescence inten-
sity across vessels using confocal microscopy (32). In the spinal 
cord white matter, CXCL12 expression was primarily abluminal on 
the vessels of male SJL mice and in C57BL/6 and B10.PL mice of 
either sex, whereas vessels in female SJL mice instead exhibited a 
unique pattern of primarily lumenal CXCL12 expression (Supple-
mental Figure 10A). Similar analyses of brain vasculature in female 
and male SJL mice revealed a predominantly lumenal display of 
CXCL12 in the brainstem and cerebellar white matter tracts in the 
female mice only, while vessels in all brain regions of male mice 
and in supratentorial brain regions of female mice exhibited proper 
abluminal patterns of CXCL12 (refs. 31, 32, and Supplemental Fig-
ure 10B). After induction of EAE, inflamed vessels within infraten-
torial regions of male mice exhibited a shift in CXCL12 expression 
from abluminal to lumenal locations, while female mice exhibited 
loss of CXCL12 expression (Supplemental Figure 11), as previously 
reported (30). To test whether inactivation of S1PR2 altered BBB 
expression of CXCL12 in vivo, we analyzed the location of CXCL12 
at CNS vasculature within the cortices, cerebella, and spinal cords 
of female SJL mice treated with vehicle or JTE-013 as well as wild-
type mice and S1pr2–/– mice at peak of disease. JTE-013–treated 
Figure 5
S1PR2 inactivation ameliorates EAE and alterations in BBB permeability. (A and B) Female SJL mice immunized with PLP139–151 were treated 
with vehicle or JTE-013 (JTE; 1.5 mg/kg) when mice reached a clinical score of 2. (A) Clinical scores of mice treated for 10 (top) or 30 (bottom) 
consecutive days ± SEM. Insets show means of cumulative scores (MCS) and of highest severity scores (MHSS) ± SEM for 10 to 15 mice per 
group. (B) H&E-stained (left panels) and LFB-stained (right panels) sections from spinal cords and cerebella of vehicle- and JTE-treated mice at 
peak of EAE (top) or remission (bottom). Bar graphs depict mean numbers of white matter lesions (WML) within both CNS regions for either peak 
or remission ± SEM for 5 to 6 mice per treatment group. Arrows highlight inflammatory foci. Scale bar: 25 μm. (C) Relative BBB permeability of 
cortex, cerebellum, and spinal cord tissues from vehicle- and JTE-treated mice at peak of EAE or remission. Data are depicted as mean fluores-
cence intensity, normalized against sera values for individual mice ± SEM for 6 mice per treatment group, with means normalized against mean 
values for untreated, naive controls. *P < 0.05; **P < 0.01; ***P < 0.001.
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female SJL mice exhibited significantly increased levels of ablu-
minal CXCL12 in infratentorial CNS regions (cerebella: P < 0.01; 
spinal cords: P < 0.05), with no changes observed in cortical vessels 
(Figure 8, A and B). Similarly, S1pr2–/– mice exhibited significantly 
higher levels of abluminal CXCL12 within spinal cord white matter 
regions than wild-type controls at peak of EAE (P < 0.001) (Figure 8, 
C and D). These data suggest that S1PR2 activity dysregulates 
proper abluminal expression of CXCL12 and that this affects dis-
ease course during CNS autoimmunity.
Discussion
We have defined a sexually dimorphic role for S1PR2 in the disrup-
tion of polarity at the BBB. Elevated levels of S1PR2 were detected 
in EAE-susceptible CNS regions in female SJL mice compared 
with that in male SJL mice and compared with C57BL/6 mice of 
both sexes. Consistent with this, antagonism of S1PR2 amelio-
rated clinical disease severity during EAE in female, but not male, 
SJL mice immunized with PLP139–151 to induce EAE. S1PR2 was 
detected on endothelial cells and vasculature-associated astro-
cytes within the CNS and was significantly higher in white matter 
regions of patients with MS compared with controls without MS, 
with female patients with MS exhibiting higher levels than male 
patients. In vivo and in vitro studies evaluating the role of S1PR2 
in BBB permeability revealed its critical involvement in loss of api-
cobasal expression of canonical markers of BBB polarity, including 
the chemokine CXCL12 (30–32). As abluminal levels of CXCL12 
control parenchymal entry of leukocytes (32, 48), our data pro-
vide strong evidence that S1PR2 acts as a general regulator of BBB 
fence function and may be targeted to treat MS in certain patients.
Recent research has characterized genetic, hormonal, and envi-
ronmental contributions to sex bias in MS; however, an under-
standing of sexual dimorphism in CNS autoimmunity has yet to 
result in novel, successful therapeutics that target these mecha-
nisms (4, 5, 49, 50). This report identifies a potential contribu-
tor to MS sex bias and is the first to identify a sexually dimorphic 
regulator of the BBB. The identification of sexually dimorphic 
changes in mRNA levels within different CNS regions was not 
due to direct effects of sex steroids on transcriptional programs. 
Thus, analysis of S1PR2 expression in the cerebella of SJL/J-Chr 
YB10.S male mice did not link sexually dimorphic effects to the 
Y chromosome (40), and analysis of S1PR2 expression in the CNS 
of naive or diseased, ovariectomized mice, with or without estra-
diol replacement, also did not reveal acute regulation of S1PR2 by 
gonadal hormones. Most current therapies for RRMS are immu-
nomodulators, while others address the consequences of relapses 
by managing symptoms or improving function (51, 52). However, 
these drugs often have off-target side effects, because they do not 
specifically target myelin-reactive leukocytes (53, 54). Targeting 
S1PR2 may avoid common off-target effects and maybe more CNS 
specific than the use of FTY720, which targets several S1PRs but 
not S1PR2 (24). As S1PR2 also maintains germinal center B cells 
(55), its blockade is unlikely to lead to the lymphopenia observed 
with FTY720. FTY720 is also associated with severe adverse events, 
including fatal herpesvirus infections, hemorrhagic focal enceph-
alitis, and vasospasm of the brachial artery, mostly mediated by 
S1PR3 signaling after prolonged use (56–62).
S1PR2 activity in our study was associated with several criti-
cal markers of endothelial barrier dysfunction, including higher 
transendothelial permeability and loss of apicobasal polarity, in 
vitro and in vivo. Our findings corroborate in vitro prior reports, 
suggesting counterbalancing roles of S1PR1 and S1PR2 in main-
taining vascular endothelial integrity via Rho GTPase signaling, 
with S1PR1 enhancing barrier function primarily via Rac activa-
tion (20, 63, 64) and S1PR2 disrupting barrier function through 
cytoskeletal contraction, stress fiber formation, and junction pro-
tein disassembly via RhoA/ROCK signaling (29, 65). Our results also 
implicate potentially complementary roles for RhoA and CDC42, a 
key regulator of cellular polarity (66), in S1PR2-mediated BBB dys-
regulation, perhaps by convergent downstream effector signaling 
(67). The caveolin-dependent endocytic pathway, but not the clath-
rin-dependent endocytic or macropinocytic pathways, also appears 
to be an important mediator of barrier dysregulation via S1PR2, 
likely due to the enrichment of S1PRs in close proximity with their 
associated effectors in membrane caveolae (64), though evidence 
Figure 6
S1PR2 deficiency ameliorates EAE and alterations in BBB permeability. Wild-type and S1pr2–/– mice were immunized with MOG and followed 
for disease progression. (A) Clinical EAE scores ± SEM. The inset shows mean of cumulative score and highest severity score ± SEM for 10 to 
15 mice per genotype. (B) H&E-stained (left panels) and LFB-stained (right panels) sections derived from spinal cords and cerebella of WT and 
S1pr2–/– mice at peak of EAE. Scale bar: 25 μm. Bar graphs depict mean numbers of white matter lesions within both CNS regions ± SEM for 
4 to 6 mice per genotype. (C) Relative BBB permeability of cortex, cerebellum, and spinal cord tissues derived from WT and S1pr2–/– mice at 
peak and chronic stages of monophasic EAE. Data are depicted as mean fluorescence intensity, normalized against plasma values for individual 
mice ± SEM for 4 to 6 mice per genotype, with means normalized against mean values for WT naive controls. *P < 0.05; **P < 0.01; ***P < 0.001.
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Figure 7
S1PR2 signaling dysregulates CNS 
endothelial barrier structure and func-
tion through Rho/ROCK, CDC42, 
and caveolin endocytosis-dependent 
pathways. (A–F) Paracellular perme-
ability of in vitro BBB cultures was 
assessed by electrode recording of 
TEER, reported in Ω/cm2. (A) TEER 
after treatment of in vitro BBB cultures 
with 10, 100, or 1,000 nM exogenous 
S1P for 4 hours or (B and C) 1,000 nM 
S1P for 4 hours with or without (B) 
1,000 nM JTE-013 at 2 hours or (C) 
the S1PR1-specific antagonist W146 
(1,000 nM) at 2 hours. (D–F) TEER 
after 1,000 nM S1P treatment of BBB 
cultures pretreated for 2 hours with 
(D) the caveolin endocytosis inhibi-
tor MBCD (10 mM), (E) Rho-associ-
ated protein kinase (ROCK) inhibitor 
H1152P (10 nM), or (F) CDC42 inhib-
itor ML141 (100 nM). TEER values 
are mean ± SEM of 6 to 9 replicates 
of 2 to 3 independent experiments. 
***P < 0.001, repeated-measures 2-way 
ANOVA. (G–L) Immunocytochemical 
staining of AJs in HCMEC/D3 cells 
via labeling of VE-cadherin (red, left 
and middle panels; scale bar: 30 μm) 
and confocal z-stack reconstruction of 
HCMEC/D3 cells (right panels; scale 
bar: 15 μm), demonstrating polar-
ized expression of canonical apical 
marker GGT-1 (green) and basolateral 
CXCL12 (red) after treatment with (G) 
vehicle or 1,000 nM S1P for 4 hours 
followed by treatment with (H) JTE, (I) 
W146, (J) MBCD, (K) H1152P, or (L) 
ML141 treatment at 2 hours. Inhibitor 
concentrations in H–L are identical to 
those in B–F. Immunocytochemical 
images are representative images of 2 
to 3 independent experiments. IC, iso-
type controls.
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Methods
Animals. SJL/JOrlCrl mice (SJL, Charles River); C57BL/6, C57BL/10, and 
SJL/J-Chr YB10.S mice (The Jackson Laboratory); B6129SF1 and 129S6/
SvEvTac mice (Taconic Farms); and S1pr2–/– mice were maintained in 
pathogen-free conditions (Department of Comparative Medicine, Wash-
ington University, St. Louis, Missouri, USA). The S1pr2–/– mice, which are 
on a B6129S background, were generated and genotyped as previously 
described (85). All mice were 10 weeks old when used for experiments.
Microarray analysis. Naive female and male SJL littermates (n = 6) were 
intracardially perfused with RNAlater (Ambion, Life Technologies), fol-
lowed by dissection of the cerebella and frontal cortices (2 mm). Tissue 
was quickly frozen in TRIzol (Ambion, Life Technologies), and RNA was 
extracted via standardized protocols. Transcriptional profiling was done 
using the Illumina Mouse6 Expression BeadChip v2 (Illumina Inc.). 100 ng 
total RNA was used to produce an amplified pool of biotin-labeled RNA 
corresponding to the polyadenylated mRNA fraction. Biotinylated RNA 
was hybridized to the array and stained with fluorescently labeled anti- 
biotin antibody. Then, the BeadChip was scanned on an Illumina 
BeadArray Reader (Illumina Inc.). Raw data were imported into Partek 
Genomics Suite (Partek Incorporated) for further characterization of sex-
ually dimorphic gene expression in female cerebella. Microarray data were 
deposited in GEO (accession no. GSE55718).
Antibodies. The following antibodies were used for IHC or Western blot-
ting: goat anti-mouse albumin conjugated to HRP (Novus); biotinylated 
rabbit polyclonal anti-human CXCL12 (Peprotech); rabbit anti-S1PR2/
Edg-5 and rabbit anti-S1P1/Edg-1 antibodies (Acris Antibodies Inc.); 
mouse anti–β-tubulin (Sigma-Aldrich); monoclonal mouse anti-human 
VE cadherin, monoclonal rat anti-mouse, and rat anti-human CD31 
(BD Bioscience); mouse monoclonal anti-human glial fibrillary acidic 
protein (GFAP) and goat anti-mouse PDFG-Rb (R&D Systems); rabbit 
anti-VE cadherin/phospho Y658 and rabbit anti–GGT-1 (Abcam Inc.); rat 
anti-human GFAP (Invitrogen, Life Technologies); IgG isotype antibod-
ies (mouse and rabbit, Invitrogen, Life Technologies; rat, BD Bioscience); 
conjugated-secondary antibodies, streptavidin conjugates, and nuclear 
stains (Molecular Probes); and IRDye-conjugated secondary antibodies 
for Western blots (LI-COR Biosciences Inc.).
QPCR. Total RNA derived from CNS tissues was prepared and QPCR was 
performed as previously described (86). Amplification of S1PR2 was done 
using 5′-ATGGGCGGCTTATACTCAGAG-3′ (sense) and 5′-GACGGA-
GAAGATGGTGACCAC-3′ (anti-sense) primers as reported by Edsbagge 
(87). QPCR products were validated via sequencing by the Protein and 
Nucleic Acid Chemistry Laboratory at Washington University.
Western blotting for S1PR2 in murine CNS. Protein lysates (40 μg) of CNS tis-
sues derived from 10-week-old SJL and C57BL/6 mice of both sexes (n = 8) 
and after ovariectomy, with and without treatment with 17β-estradiol or 
placebo, were prepared in RIPA buffer supplemented with 1:100 protease 
inhibitor cocktail and 1:100 phosphatase inhibitor cocktail-3 (all from 
Sigma-Aldrich) and resolved with 10% Bis-Tris gels and transferred onto 
iBlot Nitrocellulose transfer membranes (both from Invitrogen) accord-
ing to standard protocols. Blots were probed with polyclonal rabbit anti-
S1PR2 antibody. Total protein loading per lane was evaluated with mouse 
anti–β-tubulin antibody. This was followed by incubation with IRDye-con-
jugated secondary antibodies (LI-COR). Blots were imaged with the Odys-
sey fluorescent scanning system (LI-COR).
Ovariectomy and hormone replacement in female SJL mice. Female SJL mice 
were ovariectomized at 6 weeks of age mice prior to sexual maturity via stan-
dard protocols (33). Briefly, anesthetized animals underwent a 1-cm trans-
verse midlumbar skin incision, followed by blunt dissection of underlying 
musculature. The ovarian fat pad was exteriorized, ovarian vessels were 
ligated, and ovaries were excised, followed by skin closure with nonabsorb-
also suggests that AJs can be disrupted via caveolin-mediated endo-
cytosis of junction proteins (13, 68, 69). Of interest, interferon-beta, 
which prevents inflammatory events in RRMS, promotes stability 
of VE-cadherin (70), suggesting that the specific targeting of this 
pathway could greatly improve therapy. Finally, as S1PR2 antago-
nism does not affect receptor expression by endothelial cells (71), 
targeting the receptor to prevent alterations in BBB permeability 
should not lead to long-term effects on BBB function.
Association of S1PR2 with endothelial permeability by VE-cad-
herin–mediated tight junction dysfunction was first reported by 
Sanchez et al. using an in vitro model of HUVECs genetically mod-
ified to express S1PR2 (72). However, the observed amelioration 
of EAE in S1PR2-deficient mice could be attributed potentially 
to other immune mechanisms that do not incorporate effects 
of endothelial barriers. Among the possibilities are the effects of 
receptor deficiency on astrocytes or pericytes (73–76); the absence 
of antigen capture, as observed in vitro for Langerhans cells (77) 
and alveolar macrophages (78); or loss of B cell retention at germi-
nal centers (79, 80), which could alter their ability to function as 
effector or antigen-presenting cells within the CNS. Last, S1PR2 
signaling is required for degranulation and cytokine release by 
activated mast cells (81, 82), which have been implicated in the 
neuropathogenesis of MS and EAE (83).
We reported previously that postcapillary venules in the cen-
ter of MS lesions display the normally abluminal chemokine, 
CXCL12, aberrantly along lumenal surfaces (30–32, 84). In our 
study, altered patterns of CXCL12 expression at the BBB were 
found to be associated specifically with MS compared with other 
neuroinflammatory conditions, including viral encephalitis and 
CNS lymphoma (31). Redistributed CXCL12 was associated with 
increased activation of CXCR4 on leukocytes within vessel lumen, 
suggesting that altered CNS vasculature polarity increases leuko-
cyte capture at endothelial cell surfaces. The finding that humans 
with susceptibility for MS exhibit high levels or sexually dimor-
phic expression of S1PR2 suggests that the molecule may under-
lie susceptibility to CNS autoimmunity and might be a disease-
modifying target in MS, similar to that observed in the female 
SJL mouse. The identification of S1PR2 as a target for BBB sta-
bilization that preserves CXCL12 polarity and therefore immune 
privilege is an exciting advance toward the development of novel 
MS therapies that limit CNS inflammation without compromis-
ing immune function.
Figure 8
In vivo S1PR2 inactivation preserves BBB polarity during EAE. Detec-
tion of CD31 (green) and CXCL12 (red) within cortices, cerebella, and 
spinal cords of (A and B) female SJL mice treated with vehicle or JTE-013 
(1.5 mg/kg) or (C and D) wild-type and S1pr2–/– mice, all at peak of 
EAE. (A and C) Nuclei have been stained with Topro3 (blue). Scale bar: 
10 μm. Data are representative of approximately 30 images each from 
3 to 5 mice per treatment group. Quantification of fluorescence intensity 
during confocal microscopy for CXCL12 (red lines) and CD31 (green 
lines) is shown below microphotographs. Arrows indicate location tran-
sected in line plot depictions. (B and D) Quantitative analysis of loca-
tion of CXCL12 expression on CD31+ venules within CNS tissues of (B) 
vehicle- and JTE-013–treated and (D) wild-type and S1pr2–/– mice at 
peak of EAE. Data are derived from venules analyzed within 30 images 
per brain region for 3 to 5 mice per treatment group and are expressed 
as (mean ± SEM) percentages of vessels with abluminal, lumenal, or 
absent CXCL12 signal. *P < 0.05; **P < 0.01; ***P < 0.001 for χ2 com-
parisons between CXCL12 locations within each brain region.
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formed previously (30). Analysis of polarized expression of CXCL12 across 
vasculature was performed as previously described (32). IHC detection of 
S1PR2 was performed in a fashion similar to that outlined for human CNS 
tissues. Visualization was done by confocal microscopy, as described above.
Preparation of in vitro human BBB. In vitro human BBB cultures were gen-
erated using HCMEC/D3, an endothelial cell line developed from brain 
tissue derived from the temporal lobe of an adult human female with epi-
lepsy (88). HCMEC/D3 cells were cocultured with primary human astro-
cytes (ScienCell), within a transwell system in which TEER values (Ω/cm2) 
were measured via chopstick electrode recording with an EVOM apparatus 
(World Precision Instruments), as previously described (47). Resistance val-
ues are reported as recorded values for each replicate minus the resistance 
of cell-free inserts (∼90 Ω) measured alone. Measurements were taken 
24 hours after initial seeding of endothelial cells (day 1); subsequent mea-
surements were taken daily for 10 days, at which point cultures were ready 
for experimentation. Changes in permeability were evaluated via TEER 
measurements after vehicle or S1P (Cayman Chemical Company) was added 
to top and bottom chambers (10–1,000 nM) and incubated for 2 hours, 
followed by addition of vehicle or JTE-013 (10–1,000 nM). Similar experi-
ments were done using the following agents: S1PR1-specific agonist, W146 
(1,000 nM), and S1PR1-specific antagonist, SEW2871 (1,000 nM, both 
from Cayman Chemical Company), as well as caveolin endocytosis inhib-
itor, methyl-β cyclodextrin (MBCD, 10 nM); clathrin endocytosis inhibi-
tor, chlorpromazine (10 μg/ml); or the macropinocytosis/PI3K inhibitor, 
wortmannin (100 nM, all from Sigma-Aldrich). To determine the effector 
molecules involved in S1PR2 signaling, we also pretreated for 2 hours with 
the Rac1 inhibitor, Z62954982 (1,000 nM, Cayman Chemical Company), 
the Rho/ROCK inhibitor, H-1152P (10 nM, Cayman Chemical Company), 
and the CDC42 inhibitor, ML141 (100 nM, Tocris, R&D Systems).
In vitro RNA interference. HCMEC/D3 cells in BBB cultures or grown 
on chamber slides were treated with 25 nM siRNA SMARTpools against 
S1PR1, S1PR2, or a nontargeting control pool (ON-TARGETplus, Thermo-
Scientific) complexed with a 1:500 dilution of DharmaFect 1 transfection 
reagent (ThermoScientific) in antibiotic-free culture medium for 48 hours. 
Knockdown was confirmed via immunocytochemical analysis of S1PR1 
and S1PR2 protein expression. Following siRNA treatment, cells were 
rinsed 3 times with PBS, returned to normal culture medium, and imme-
diately used for immunostaining or TEER measurement experiments.
Immunocytochemical evaluation of in vitro human BBB. Analysis of polarized 
expression of CXCL12 within HCMEC/D3 cells was performed after fixa-
tion with 4% paraformaldehyde for 60 minutes and permeabilization with 
0.1% Triton X-100 and 10% goat serum for 30 minutes at room tempera-
ture. HCMEC/D3 cultures were incubated with primary antibodies against 
GGT-1, VE-cadherin, and biotinylated CXCL12 in 10% goat serum for 
60 minutes at room temperature. Cells were washed 3 times in 1X dPBS 
and then incubated in goat anti-rabbit Alexa Fluor 555 and goat anti-
mouse Alexa Fluor 488 or Alexa Fluor 555 and streptavidin–Alexa Fluor 
555 secondary antibodies in 10% goat serum for 15 minutes at room 
temperature. Cells were washed, counterstained with To-Pro-3, and cover-
slipped before being visualized via confocal microscopy.
Statistics. All microarray statistical analyses for the characterization of 
sexually dimorphic gene expression in female cerebella were performed 
using Partek Genomics Suite (Partek Incorporated). Data were filtered 
for detectable probes (Illumina detection using P < 0.05 in at least one 
sample yielded 27,333 probes), quantile normalized by CNS region, and 
submitted to 2-way ANOVA for sex- and region-specific gene regulation. 
Transcripts that demonstrated upregulation or downregulation of >1.3 
with a false discovery rate <0.2 were selected for further characterization. 
Two-tailed, Student’s t test was used to determine the statistical signif-
icance of immunohistochemical, mean maximal disease severity, and 
able sutures. Hormonal replacement was initiated 14 days after ovariectomy 
by subcutaneous implantation of either 0.25 mg 17β-estradiol or placebo 
(vehicle) 21-day release pellets (Innovative Research of America). A cohort 
of these mice was immunized with PLP139–151, together with sham-ovariecto-
mized mice, to induce EAE 7 days after hormone replacement. Immunized 
animals were followed for EAE progression by monitoring clinical score and 
body weight. Tissues were obtained from sham-ovariectomized and place-
bo-treated mice when they reached a score of 2 at 14 days after immuniza-
tion and from 17β-estradiol–treated mice, which remained free of disease, 
at 21 days after immunization. Protein lysates were prepared from CNS tis-
sues, while uteri and the upper third of vaginas of all mice were drop-fixed 
in 4% PFA for 48 hours. Following fixation, uterine tissue was trimmed of 
fat and connective tissue prior to determination of uterine weight.
EAE induction and in vivo treatment with JTE-013. EAE was induced in SJL/J 
mice via active immunization with proteolipid protein (PLP139–151; 200 μg) 
(GenScript USA Inc.) emulsified in complete Freund’s adjuvant containing 
Mycobacterium tuberculosis (H37Ra; Difco Laboratories). In addition, mice 
were injected with 200 ng pertussis toxin (List Biologicals Laboratories Inc.) 
at the time of immunization and 2 days after. Mice were graded for clinical 
manifestations of EAE by the following criteria: 1, tail weakness; 2, difficulty 
righting; 3, hind limb paralysis; 4, forelimb weakness or paralysis; 5, mori-
bund or dead. JTE-013 (1.5 mg/kg; Cayman Chemical Company) or vehicle 
(25% ETOH) was administered to mice daily via intraperitoneal injection, as 
previously described (46), when they achieved a clinical score of 2. B6129SF1 
and S1pr2–/– mice were immunized similarly with 200 μg myelin oligodendro-
cyte glycoprotein (MOG35–55; GenScript USA Inc.) and 200 μg M. tuberculosis 
adjuvant. C57BL/6 mice were immunized as previously described (32).
In vivo assessment of BBB permeability. Mice were intraperitoneally injected 
with fluorescein sodium salt (100 mg/ml, Sigma-Aldrich), followed by 
collection of blood, intracardial perfusion, and harvesting of CNS tissues. 
Homogenates and sera were incubated overnight at 4°C at 1:1 dilution in 
2% trichloroacetic acid (Sigma-Aldrich) and diluted in equal volumes of 
borate buffer, pH 11 (Sigma-Aldrich). Fluorescence emission at 538 nm 
was determined via a microplate reader, Synergy H1, and Gen5 software 
(both from BioTek Instruments Inc.). Tissue values were standardized 
against plasma values for individual mice.
Human subjects. The use of human postmortem biopsies for this study was 
approved by the Human Studies Committee of Washington University. Post-
mortem CNS tissue from 2 groups of patients was studied: 11 patients with 
clinically defined MS followed in the Washington University Multiple Sclero-
sis Center and 9 control individuals without histories of MS (Supplemental 
Table 2). The control group consisted of 8 patients without any clinical his-
tories of neurological disease and 1 patient with a history of CNS lymphoma.
IHC of S1PR2 in human CNS. Human postmortem specimens were col-
lected within 18 hours after death from 5 female and 5 male patients 
with MS and the same number of non-MS controls. Tissue preparation 
and evaluation of extent of inflammation were performed as previously 
described (31). For IHC, tissue sections were hydrated and fixed in 4% 
paraformaldehyde, blocked in 0.1% Triton X-100 and 10% goat serum, fol-
lowed by incubation with rabbit anti-S1PR2, rat anti-human CD31, mouse 
anti-human GFAP, and/or monoclonal mouse anti-human VE cadherin 
antibodies. Primary antibodies were detected with goat anti-rabbit Alexa 
Fluor 555, anti-rat Alexa Fluor 488, or goat anti-mouse Alexa Fluor 488 
antibodies, as appropriate, followed by To-Pro-3 nuclear staining, confo-
cal microscopy (Carl Zeiss USA), and quantitative analysis with Volocity 
3D Image Analysis software (PerkinElmer Inc.). HRP-conjugated primary 
antibodies were detected via development in DAB solution (Cell Marque).
Histological and immunohistochemical analyses of murine samples. Murine 
CNS tissues underwent histological analyses (H&E; LFB staining) and IHC 
detection of CD31, GFAP, PDFG-Rβ, VE-cadherin, and CXCL12, as per-
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cumulative clinical score analyses. Statistical significance of qRT-PCR, 
disease severity curve, fluorescein permeability, and TEER measure-
ments was done by 2-way ANOVA, followed by Bonferroni’s post-hoc 
test with appropriate correction for repeated measures. Comparison of 
CXCL12 polarity was done via χ2 test. For all graphs, error bars represent 
± 1 SEM. All statistical analysis was performed with GraphPad Prism 
software, version 5.0. P values of less than 0.05 were considered signifi-
cant for all comparisons.
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were performed in compliance with Washington University Institutional 
Animal Care and Use Committee (Animal Welfare Assurance A3381-01), 
which approved our animal protocol (20120160, 8/3/12). All efforts were 
made to minimize the suffering of animals used in this study. Postmortem 
human tissues banked for research purposes are exempt from institutional 
review board approval, and researchers do not have direct access to any 
identifying information.
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